Development and evaluation of a formulation for the treatment of skin aging based on studies of human skin fatty acids and their correlation with the skin microbiome

• Grant number: 24/03198-0
• Support Opportunities: Scholarships in Brazil - Doctorate
• Start date: March 01, 2025
• End date: June 30, 2027
• Field of knowledge: Health Sciences - Pharmacy
• Principal Investigator: Patricia Santos Lopes
• Grantee: Raquel Allen Garcia Barbeto Siqueira
• Host Institution: Instituto de Ciências Ambientais, Químicas e Farmacêuticas (ICAQF). Universidade Federal de São Paulo (UNIFESP). Campus Diadema. Diadema , SP, Brazil

Abstract

During aging, human skin changes macroscopically and microscopically, with the formation of wrinkles, reduction of elasticity, as well as the skin's barrier function. These phenotypic changes may be caused by exposomal factors, as well as intrinsic factors, such as pigmentation, variations anatomical and hormonal changes. One of the most important and current factors linkedThis aging is the skin's microbiota. Among the diversity of skin microorganisms, the bacterial community represents the most studied community.Studies of the human microbiome using metagenomic analysis shed light on some spots, but there are no cosmetic formulations to treat the skin condition using microbiome knowledge. Another fundamental point in this Aging is the change in the production of fatty acids in the skin. These changes begin between the ages of 25 and 35, so the use of appropriate products can delay this aging process, maintaining skin homeostasis for longer. In this context, the development of a product containing a nanostructured system containing pre and biotic powders, in addition to replacing the chosen fatty acids, can prevent skin aging since short-chain free fatty acids are responsible for maintaining a wrinkle-free appearance. The assessment will be inin two different populations (population from Europe Central and South American population) and their mutual comparison. This project falls within the TRL-3 maturity level with the objective of reaching TRL-5 by through laboratory-scale tests and clinical trials, aiming for the best understanding of obtaining lipid nanostructures, their association with pre- and biotic powders linked to the presence and prevalence of certain species ofskin microorganisms and reducing signs of aging.